Compare Nuwellis Inc (NUWE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Sana Biotechnology Inc — how do they compare? Nuwellis Inc trades at $0.79 (market cap $2.54M), while Sana Biotechnology Inc trades at $3.17 (market cap $947.48M). The key difference: Sana Biotechnology Inc is far larger — about 373× Nuwellis Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | SANA | |
|---|---|---|
Market Cap | $2.54M | $947.48M |
Sector | Technology | Health |
52-Week High | $164.50 | $5.92 |
52-Week Low | $0.73 | $2.68 |
Enterprise Value | -$1.17M | $860.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
